Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MASTER-2 Trial in Newly Diagnosed Multiple Myeloma
NCT05231629Phase 2Active, not recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Dec 2023
- Primary completion
- Sep 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab, teclistamab, bortezomib, lenalidomide, dexamethasone in multiple myeloma (MM), sponsored by University of Alabama at Birmingham. Started Dec 2023; status: active, not recruiting.
02
Drugs
daratumumabteclistamabbortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05231629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05231629.